Cui, Yue

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology

Cell death mechanisms and regulationLymphoma Diagnosis and Treatment

Cited by 876

A comprehensive review of machine learning-based state of health estimation for lithium-ion batteries: data, features, algorithms, and future challenges

Wang, Y., Guo, S., Cui, Y., Deng, L., Zhao, L., Li, J., & Wang, Z. (2025) · Renewable and Sustainable Energy Reviews

Battery Modeling and ManagementAdvancements in Battery Materials

Cited by 107